Table 4.
Proportion of days covered and discontinuation of tofacitinib during follow-up, by prior biologic history
| Overall | Biologic-naïve | 1 prior biologic | ≥ 2 prior biologic | |
|---|---|---|---|---|
| N = 225 | N = 43 | N = 92 | N = 90 | |
| Proportion of days covered during 6-month follow-up | ||||
| Mean (SD) | 0.7 (0.3) | 0.7 (0.3) | 0.7 (0.3) | 0.7 (0.3) |
| Median (IQR) | 0.8 (0.5, 1.0) | 0.8 (0.5, 1.0) | 0.9 (0.5, 1.0) | 0.8 (0.5, 1.0) |
| Discontinuation during 4 months of follow-up,a n (%) | 34 (15.1) | 9 (20.9) | 15 (16.3) | 10 (11.1) |
| Time to discontinuation during 4 months of follow-up,a days | ||||
| Mean (SD) | 42.4 (15.0) | 43.3 (15.8) | 42.0 (15.2) | 42.0 (15.5) |
| Median (IQR) | 30.0 (30.0, 60.0) | 30.0 (30.0, 60.0) | 30.0 (30.0, 60.0) | 30.0 (30.0, 60.0) |
| Sensitivity analysis (12 months of follow-up) | N = 91 | N = 16 | N = 31 | N = 44 |
|---|---|---|---|---|
| Proportion of days covered during 12-month follow-up | ||||
| Mean (SD) | 0.7 (0.3) | 0.8 (0.2) | 0.7 (0.3) | 0.6 (0.3) |
| Median (IQR) | 0.8 (0.4, 1.0) | 0.8 (0.6, 0.9) | 0.8 (0.5, 1.0) | 0.6 (0.3, 1.0) |
| Discontinuation during 10 months of follow-up,a n (%) | 36 (39.6) | 4 (25.0) | 10 (32.3) | 22 (50.0) |
| Time to discontinuation during 10 months of follow-up,a days | ||||
| Mean (SD) | 120.0 (67.8) | 177.8 (61.7) | 131.1 (72.0) | 104.4 (62.8) |
| Median (IQR) | 99.5 (63.5, 180.0) | 198.0 (135.0, 220.5) | 105.5 (90.0, 180.0) | 94.5 (60.0, 150.0) |
The ideal proportion of days covered is 1.0
IQR, interquartile range; SD, standard deviation
aPatients were not considered at risk of discontinuing therapy in the last 60 days of their follow-up because of the required 60-day gap to define discontinuation. Therefore, discontinuation was only calculated up to 60 days before the end of the follow-up period